SEC Form 4 · accession 0001104659-16-160108
NOVELION THERAPEUTICS INC. · NVLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barbara Y Chan
Officer — See Remarks
Period of report
Nov 29, 2016
Accepted (ET)
Dec 1, 2016 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827809
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F1 | $1.55 | Nov 29, 2016 | A | 26,665 | A | — | — | Common Shares | 26,665 | 26,665 | D |
Explanation of responses
- F125% of the common shares underlying this stock option award will vest on July 1, 2017. The remaining 75% of the common shares underlying this stock option award will vest thereafter in equal monthly installments through July 1, 2020, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer or any of its subsidiaries.
- F2Pursuant to the Agreement and Plan of Merger, dated as of June 14, 2016, by and among the Issuer, Aegerion Pharmaceuticals, Inc. ("Aegerion") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into Aegerion, effective on November 29, 2016, the option to purchase common shares of the Issuer was received in exchange for an option to purchase 26,000 shares of Aegerion common stock.
Remarks
President and Chief Accounting Officer, Aegerion Pharmaceuticals, Inc.